Evidence-based pharmacotherapy of generalized anxiety disorder

International Journal of Neuropsychopharmacology

Volumn 8, Issue 2, 2005, Pages 293-302

  Baldwin, David S ^a,b   Polkinghorn, Claire ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Drug treatment; Generalized Anxiety Disorder

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BROMAZEPAM; BUSPIRONE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOMIPRAMINE; DELORAZEPAM; DIAZEPAM; ESCITALOPRAM; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; HYDROXYZINE; IMIPRAMINE; PAROXETINE; PLACEBO; PREGABALIN; PROPANOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GENERALIZED ANXIETY DISORDER; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHOOL CHILD; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 20044384075     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004870     Document Type: Review

References (73)

1. Allgulander C, Cloninger CR, Przybeck TR, Brandt L (1998). Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacology Bulletin 34, 165-166.
2. Allgulander C, Hackett D, Salinas E (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. British Journal of Psychiatry 179, 15-22.
3. Ansseau M, Papart P, Gerard MAA, von Frenckell R, Franck G (1990). Controlled comparison of buspirone and oxazepam in generalised anxiety. Neuropsychobiology 24, 74-78.
4. Argyropoulos SV, Nutt DJ (1999). The use of benzodiazepines in anxiety and other disorders. European Neuropsychopharmacology 9 (Suppl. 9), S407-S412.
5. Baldwin DS (2001). SSRIs in the treatment of generalised anxiety disorder. In: Montgomery SA, den Boer JA (Eds.), SSRIs in Depression and Anxiety, (pp. 193-209). Chichester: Wiley.
6. Baldwin DS, McCafferty J, Bellew K, Bryson H, Adams A, Hewett K, Iyengar M (2002). Improving the disability and impairment associated with generalised anxiety disorder with paroxetine treatment. International Journal of Neuropsychopharmacology 5 (Suppl. 1), S213.
7. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry 3, 171-199.
8. Beekman AT, Bremmer MA, Deeg DJ, van Balkom AJ, Smit JH, de Beurs E, van Dyck R, van Tilburg W (1998). Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. International Journal of Geriatric Psychiatry 13, 717-726.
9. Bradford LD, Stevens G (1994). Double-lind, placebo-controlled fixed dose study of flesinoxan in generalized anxiety disorder. American College of Neuropsychopharmacology 167.
10. Carter RM, Wittchen H-U, Pfisster H, Kessler RC (2001). One-year prevalence of subthreshold and threshold DSM-FV generalised anxiety disorder in a nationally representative sample. Depression and Anxiety 13, 78-88.
11. Charney DS, Woods SW, Heninger GR (1989). Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Research 27, 173-182.
12. Connor KM, Davidson JRT (1998). Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biological Psychiatry 44, 1286-1294.
13. Darcis T, Ferreri M, Natens J, Burtin B, Deram P and the French GP Study Group for Hydroxyzine (1995). A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety disorder. Human Psychopharmacology 10, 181-187.
14. Davidson J, Bose A, Su G (2002). Escitalopram in the treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 5 (Suppl. 1), S214.
15. Davidson JRT, Ballenger JC, Lecrubier Y, Nutt DJ (2001). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry 62 (Suppl. 11), 46-52.
16. Davidson JR, DuPont RL, Hedges D, Haskins JT (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalised anxiety disorder. Journal of Clinical Psychiatry 60, 528-535.
17. Durham RC, Fisher PL, Trevling LR (1999). One year follow-up of cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder: symptom change, medication usage and attitudes to treatment. Behavioural and Consulting Psychotherapy 27, 19-35.
18. Durham RC, Turvey AA (1987). Cognitive therapy versus behaviour therapy in the treatment of chronic generalised anxiety. Behavior Research and Therapy 25, 229-234.
19. Fairbanks JM, Pine DS, Tancer NK, Dummit 3rd ES, Kentgen LM, Martin J, Asche BK, Klein RG (1997). Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. Journal of Child and Adolescent Psychopharmacology 7, 17-29.
20. Feighner JP, Entsuah AR, McPherson MK (1998). Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. Journal of Affective Disorders 47, 55-62.
21. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC (2003). A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240-249.
22. Gammans RE, Stringfellow JC, Hvidzos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickeis K (1992). Use of buspirone in patients with generalised anxiety disorder and coexisting depressive symptoms: a meta-analysis of eight randomised controlled trials. Neuropsychobiology 25, 193-201.
23. Goa KL, Ward A (1986). Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32, 114-129.
24. Goldberg HL, Finnerty RJ (1979). The comparative efficacy of buspirone and diazepam in the treatment of anxiety. American Journal of Psychiatry 136, 1184-1187.
25. Gorman J (2002). Treatment of generalised anxiety disorder. Journal of Clinical Psychiatry 63 (Suppl.), 17-23.
26. Gorman JM, Korotzer A, Su G (2002). Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectrums 7 (Suppl. 1), S40-S44.
27. Gould RA, Otto MW, Pollack MH, Yap L (1997). Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behavior Therapy 28, 285-305.
28. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ (1999). The economic burden of anxiety disorders in the 1990s. Journal of Clinical Psychiatry 60, 427-435.
29. Guy W (1976). CDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare. DHEW Publication no. ADM 218-222. Kensington, MD: The George Washington University.
30. Hackett D, Haudiquet V, Salinas E (2000). Controlling for the placebo response rate: a methodological approach to data from double-blind studies with a high placebo response. Presented at British Association for Psychopharmacology, Harrogate.
31. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50-55.
32. Hamilton M (1967). Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6, 278-296.
33. Hurst M, Lamb HM (2000). Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 14, 51-80.
34. Hyttel J, Bsego KP, Perregard JA, Sanchez C (1992). The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. Journal of Neural Transmission General Section 88, 157-160.
35. Jefferson J, Greist J (2000). A double-blind comparison of citalopram and paroxetine in the treatment of patients with depression and anxiety. Presented at the American College of Neuropsychopharmacology, December.
36. Kapczinski F, Schmitt R, Lima MS (2003). The use of antidepressants for Generalized Anxiety Disorder. Cochrane Database of Systematic Reviews.
37. Katz IR, Reynolds C, Alexopoulos GS, Hackett D (2002). Venlafaxine ER as treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. Journal of the American Geriatric Society 50, 18-25.
38. Kessler RC, DuPont RL, Berglund P, Wittchen H-U (1999). Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. American Journal of Psychiatry 156, 1915-1923.
39. Lader M, Scotto JC (1998). A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 139, 402-406.
40. Lader MH (1999). Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? European Neuropsychopharmacology 9 (Suppl. 9), S399-S405.
41. Lader MH, Bond AJ (1998). Interaction of pharmacological and psychological treatments of anxiety. British Journal of Psychiatry 373 (Suppl. 34), 42-48.
42. Llorca PM, Sapdone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D (2002). Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a three-month double-blind study. Journal of Clinical Psychiatry 63, 1020-1027.
43. Maier W, Falkai P (1999). The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. International Clinical Psychopharmacology 34 (Suppl. 2), 51-56.
44. Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR (1987). Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. Journal of Clinical Psychiatry 84, 355-358.
45. Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, Sebastian JA, Semchyshyn G, Durr MJ, Melmed AS (1986). Effective short-term treatment of generalized anxiety with trifluoperazine. Journal of Clinical Psychiatry 47, 170-174.
46. Montgomery SA (2003). Pregabalin in generalized anxiety disorder: speed of onset. European Neuropsychopharmacology 13 (Suppl. 4), S376.
47. Montgomery SA, Mahe V, Haudiquet V, Hackett D (2002a). Effectiveness of venlafaxine, extended release formulation, in short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. Journal of Clinical Psychopharmacology 22, 561-567.
48. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D (2002b). Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Journal of Psychiatric Research 36, 209-217.
49. Morris PLP, Dahl AA, Kutcher SP, Sogaard JA, Allgfulander C, Burt T (2003). Efficacy of sertraline for the acute treatment of generalized anxiety disorder (GAD). European Neuropsychopharmacology 13 (Suppl. 4), S375.
50. Pande AC, Crockatt JG, Janney C, et al. (2000). Pregabalin, a novel agent, in the treatment of generalized anxiety disorder. Presented at American Psychiatric Association, San Diego, May.
51. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350-357.
52. Power KG, Simpson RJ, Swanson V, Wallace LA (1990). Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. British Journal of General Practice 40, 289-294.
53. Rickels K, Downing R, Schweizer E, Hassman H (1993). Antidepressants for the treatment of generalised anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. Archives of General Psychiatry 50, 884-898.
54. Rickels K, Pollack MH, Lydiard RB, Bielski DE, Feltner AC, Pande AC, Kavoussi RJ (2002). Comparison of the efficacy and safety of pregabalin and alprazolam in generalised anxiety disorder. International Journal of Neuropsychopharmacology 5 (Suppl. 1), S213.
55. Rickels K, Pollack MH, Sheehan DV, Haskins JT (2000). Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. American Journal of Psychiatry 157, 968-974.
56. Rickels K, Zaninelli R, McCafferty JP, Bellew K, Iyengar M, Sheehan D (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749-756.
57. Rocca P, Ferrero P, Gualerzi A, Zanalda E, Maina G, Bergamasco B, Ravizza L (1991). Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatrica Scandinavica 84, 537-544.
58. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L (1997). Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica 95, 444-450.
59. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S (1994). Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. International Clinical Psychopharmacology 9 (Suppl. 1), 41-48.
60. Rynn MA, Siqueland L, Rickels K (2001). Placebo-controlled trial of sertraline in the treatment of children with generalised anxiety disorder. American Journal of Psychiatry 158, 2008-2014.
61. Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J (1989). Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biological Psychiatry 25, 141-152.
62. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. International Clinical Psychopharmacology 11 (Suppl. 3), 89-95.
63. Sjodin I, Kutcher SP, Ravindran A, Burt T (2003). Efficacy of sertraline in improving quality of life and functioning in generalized anxiety disorder. European Neuropsychopharmacology 13 (Suppl. 4), S365.
64. Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M (1999). Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. Journal of Clinical Psychiatry 60, 580-583.
65. Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR (1996). Efficacy of buspirone in generalised anxiety disorder with coexisting mild depressive symptoms. Journal of Clinical Psychiatry 57, 287-291.
66. Stahl S (2000). Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biological Psychiatry 48, 894-901.
67. Stocchi FG, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK, Paroxetine Generalized Anxiety Disorder Study Team (2003). Efficacy and tolerability of paroxetine for the long-term treatment of generalised anxiety disorder. Journal of Clinical Psychiatry 64, 250-258.
68. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL (2002). Paroxetine - an update of its use in psychiatric disorders in adults. Drugs 62, 655-703.
69. Weiller E, Bisserbe JC, Maier W, Lecrubier Y (1998). Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health Care. British Journal of Psychiatry 173 (Suppl. 34), 18-23.
70. Weizman R, Tanne Z, Granek M, Karp L, Colomb M, Tyano S, Gavish M (1987). Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. European Journal of Pharmacology 138, 289-292.
71. Wittchen HU (2002). Generalized anxiety disorder: prevalence, burden and cost to society. Depression and Anxiety 16, 162-171.
72. Wittchen HU, Carter RM, Pfisster H, Montgomery SA, Kessler RC (2000). Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. International Clinical Psychopharmacology 15, 319-328.
73. Yonkers KA, Dyck IR, Warshaw M, Keller MB (2000). Factors predicting the clinical course of generalised anxiety disorder. British Journal of Psychiatry 176, 544-549.